Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events?
LDL-cholesterol
LDL-cholesterol corrected for its content in Lipoprotein(a) particles
Lipoprotein(a)
cardiovascular events
lipoprotein apheresis
targets for LDL-cholesterol
Journal
Journal of cardiovascular development and disease
ISSN: 2308-3425
Titre abrégé: J Cardiovasc Dev Dis
Pays: Switzerland
ID NLM: 101651414
Informations de publication
Date de publication:
16 Jul 2020
16 Jul 2020
Historique:
received:
22
06
2020
revised:
14
07
2020
accepted:
15
07
2020
entrez:
26
7
2020
pubmed:
28
7
2020
medline:
28
7
2020
Statut:
epublish
Résumé
Lipoprotein apheresis (LA) is an effective tool to reduce cardiovascular events (CVEs) in high-risk patients with elevations of low density lipoprotein-cholesterol (LDL-C) and/or Lipoprotein(a) (Lp(a)). All patients included into this retrospective analysis had experienced CVEs before the start of the LA therapy. We compared personal and lab data in two groups: CVEx/0 (
Identifiants
pubmed: 32708542
pii: jcdd7030025
doi: 10.3390/jcdd7030025
pmc: PMC7569841
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Atheroscler Suppl. 2017 Nov;30:209-216
pubmed: 29096840
J Cardiovasc Dev Dis. 2018 May 09;5(2):
pubmed: 29747383
Circulation. 2013 Dec 17;128(24):2567-76
pubmed: 24056686
Curr Opin Lipidol. 2015 Jun;26(3):169-78
pubmed: 25943842
Atheroscler Suppl. 2013 Jan;14(1):39-44
pubmed: 23357139
Clin Res Cardiol Suppl. 2017 Mar;12(Suppl 1):44-49
pubmed: 28233268
Atherosclerosis. 2000 Oct;152(2):519-26
pubmed: 10998482
J Clin Lipidol. 2019 May - Jun;13(3):374-392
pubmed: 31147269
Nat Clin Pract Cardiovasc Med. 2009 Mar;6(3):229-39
pubmed: 19234501
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Arterioscler Thromb Vasc Biol. 2016 Sep;36(9):2019-27
pubmed: 27417585
Atheroscler Suppl. 2013 Jan;14(1):45-50
pubmed: 23357140
Med Devices (Auckl). 2016 Oct 13;9:349-360
pubmed: 27785114